Published in Ann Intern Med on April 15, 1997
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut (2002) 2.00
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol (2015) 1.84
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Pharmacogenomics in the clinic. Nature (2015) 1.71
6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2014) 1.70
Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. JAMA Oncol (2015) 1.55
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2011) 1.53
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Therapeutic lessons from pharmacogenetics. Ann Intern Med (1997) 1.13
Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10
The thiopurines: an update. Invest New Drugs (2005) 1.05
Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol (2003) 1.05
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol (2010) 1.00
Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut (2003) 0.98
Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol (2008) 0.95
Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol (2008) 0.94
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet (2016) 0.93
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Systems biology and functional genomics approaches for the identification of cellular responses to drug toxicity. Expert Opin Drug Metab Toxicol (2008) 0.92
Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol (2004) 0.92
Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2001) 0.91
A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clin Pharmacol Ther (2013) 0.91
The application of mass-spectrometry-based protein biomarker discovery to theragnostics. Br J Clin Pharmacol (2010) 0.91
Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest (1998) 0.91
Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol (2011) 0.90
Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol (2010) 0.88
Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics (2013) 0.88
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? Br J Clin Pharmacol (2015) 0.87
Using genetics to deliver personalized SLE therapy-a realistic prospect? Nat Rev Rheumatol (2010) 0.87
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung (2010) 0.87
Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol (2001) 0.86
Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol (2010) 0.86
Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol (2004) 0.85
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn (2007) 0.85
Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer (2014) 0.84
Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol (2003) 0.83
Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. Eur J Clin Pharmacol (2010) 0.83
Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist (2011) 0.83
Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait. Clin Pharmacol Ther (2016) 0.82
Pharmacogenomics--how close/far are we to practising individualized medicine for children? Br J Clin Pharmacol (2015) 0.82
Genetic analysis of thiopurine methyltransferase polymorphism in the Jordanian population. Eur J Clin Pharmacol (2010) 0.82
The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. Can J Gastroenterol (2013) 0.81
Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients. Dig Dis Sci (2012) 0.81
Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups. Br J Clin Pharmacol (2004) 0.81
Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol (2007) 0.81
Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr (2013) 0.81
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J (2002) 0.80
DMET™ (Drug Metabolism Enzymes and Transporters): a Pharmacogenomic platform for precision medicine. Oncotarget (2016) 0.80
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
Screening for 392 polymorphisms in 141 pharmacogenes. Biomed Rep (2014) 0.80
Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. Exp Ther Med (2011) 0.80
Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. World J Gastroenterol (2009) 0.79
Validation of new allele-specific real-time PCR system for thiopurine methyltransferase genotyping in Korean population. Biomed Res Int (2013) 0.79
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine. Br J Clin Pharmacol (1999) 0.78
Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population. Libyan J Med (2015) 0.78
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. Acta Pharmacol Sin (2015) 0.78
Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. Eur J Clin Pharmacol (2004) 0.78
Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients. World J Gastroenterol (2014) 0.78
TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer (2009) 0.78
High-resolution melting analysis of the TPMT gene: a study in the Polish population. Genet Test Mol Biomarkers (2012) 0.78
Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist (2011) 0.78
TPMT*26 (208F-->L), a novel mutation detected in a Chinese. Br J Clin Pharmacol (2009) 0.78
The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics (2017) 0.78
Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease. Yonsei Med J (2014) 0.77
Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease. Ann Gastroenterol (2012) 0.77
Thiopurine methyltransferase genotyping in Palestinian childhood acute lymphoblastic leukemia patients. BMC Hematol (2013) 0.77
Azathioprine metabolite measurements are not useful in following treatment of autoimmune hepatitis in Alaska Native and other non-Caucasian people. Can J Gastroenterol (2011) 0.77
Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies. Pharmgenomics Pers Med (2010) 0.77
Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol (2009) 0.77
Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol (2014) 0.77
Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol (2006) 0.76
Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions. Expert Opin Drug Metab Toxicol (2009) 0.76
Enhanced specificity of TPMT*2 genotyping using unidirectional wild-type and mutant allele-specific scorpion primers in a single tube. PLoS One (2014) 0.76
Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci (2016) 0.75
Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia. Iran J Ped Hematol Oncol (2014) 0.75
Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy. Pharmacogenomics J (2016) 0.75
Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases. EPMA J (2011) 0.75
Molecular diagnosis of thiopurine S-methyltransferase deficiency. Ann Intern Med (1997) 0.75
Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood (2017) 0.75
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med (2017) 0.75
Thiopurine S-methyltransferase alleles, TPMT(*)2, (*)3B and (*)3C, and genotype frequencies in an Indian population. Exp Ther Med (2010) 0.75
A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs. Mol Diagn Ther (2016) 0.75
Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine. Br J Pharmacol (2011) 0.75
Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: a systematic review. Pharmacogenomics (2016) 0.75
Pharmacogenomics of adverse effects of anti-leukemic agents in children. J Pediatr Pharmacol Ther (2012) 0.75
Lack of effect of intravenous azathioprine on time to respond for steroid treated Crohn's disease. Gut (2001) 0.75
Common Pitfalls in Management of Inflammatory Bowel Disease. Gastroenterology Res (2009) 0.75
Gene mutation of thiopurine S-methyltransferase in Uygur Chinese. Eur J Clin Pharmacol (2004) 0.75
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood (1995) 2.89
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res (1999) 1.67
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol (2000) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
Review of small bowel obstruction at Milwaukee County General Hospital. Am J Surg (1966) 1.56
Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol (2001) 1.56
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst (1996) 1.54
Determination of viability of ischemic intestine by Doppler ultrasound. Surgery (1978) 1.54
Bypass grafting to distal arteries for limb salvage. Surg Gynecol Obstet (1972) 1.54
Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol (1998) 1.52
Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant (2001) 1.52
Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther (1994) 1.51
Lineage switch in acute leukemia. Blood (1984) 1.51
Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther (1992) 1.51
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood (2001) 1.50
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Childhood acute lymphoblastic leukaemia--current status and future perspectives. Lancet Oncol (2001) 1.48
Cardiovascular risk factors in patients with peripheral vascular disease. Surgery (1978) 1.44
Acute suppurative cholangitis. Experience with 15 consecutive cases. Arch Surg (1967) 1.43
Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer (1997) 1.42
Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol (1991) 1.42
Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. J Natl Cancer Inst (2012) 1.41
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40